These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35524007)

  • 1. Management strategies in heart failure with preserved ejection fraction.
    Wintrich J; Abdin A; Böhm M
    Herz; 2022 Aug; 47(4):332-339. PubMed ID: 35524007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heart failure with preserved ejection fraction (HFpEF). What's up?].
    Trokart R; Tridetti J; Melissopoulou M; Nguyen-Trung ML; Troisfontaines P; Lancellotti P
    Rev Med Liege; 2022 Oct; 77(10):593-602. PubMed ID: 36226396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
    Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Applicability of H
    Jia XY; Liu LX; Wang DW; Ma XW; Liu YM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):154-160. PubMed ID: 38686710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the H
    Tada A; Nagai T; Omote K; Iwano H; Tsujinaga S; Kamiya K; Konishi T; Sato T; Komoriyama H; Kobayashi Y; Takenaka S; Mizuguchi Y; Sato T; Yamamoto K; Yoshikawa T; Saito Y; Anzai T
    Int J Cardiol; 2021 Nov; 342():43-48. PubMed ID: 34364907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
    Wintrich J; Kindermann I; Ukena C; Selejan S; Werner C; Maack C; Laufs U; Tschöpe C; Anker SD; Lam CSP; Voors AA; Böhm M
    Clin Res Cardiol; 2020 Sep; 109(9):1079-1098. PubMed ID: 32236720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction.
    Hias J; Hellemans L; Walgraeve K; Tournoy J; Van der Linden L
    Drugs Aging; 2022 Mar; 39(3):185-190. PubMed ID: 35118602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
    Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
    Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
    Schneider CA; Pfister R
    Herz; 2022 Oct; 47(5):395-400. PubMed ID: 36018379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generalizability of HFA-PEFF and H
    Faxen UL; Venkateshvaran A; Shah SJ; Lam CSP; Svedlund S; Saraste A; Beussink-Nelson L; Lagerstrom Fermer M; Gan LM; Hage C; Lund LH
    J Card Fail; 2021 Jul; 27(7):756-765. PubMed ID: 33647474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of the HFA-PEFF and H
    Tomasoni D; Aimo A; Merlo M; Nardi M; Adamo M; Bellicini MG; Cani D; Franzini M; Khalil A; Pancaldi E; Panichella G; Porcari A; Rossi M; Vergaro G; Lombardi CM; Sinagra G; Rapezzi C; Emdin M; Metra M
    Eur J Heart Fail; 2022 Dec; 24(12):2374-2386. PubMed ID: 35855616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors in heart failure with preserved ejection fraction.
    Faluk M; Wardhere A; Thakker R; Khan FA
    Curr Probl Cardiol; 2024 Mar; 49(3):102388. PubMed ID: 38184133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications.
    Plosker A; Frishman WH
    Cardiol Rev; 2024 May-Jun 01; 32(3):263-266. PubMed ID: 36728757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.
    Meifang W; Ying W; Wen C; Kaizu X; Meiyan S; Liming L
    Heart Fail Rev; 2024 Mar; 29(2):305-320. PubMed ID: 37561223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation the value of H
    Wang Z; Fang J; Hong H
    Acta Cardiol; 2023 Sep; 78(7):790-795. PubMed ID: 37318053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).
    Tschöpe C; Birner C; Böhm M; Bruder O; Frantz S; Luchner A; Maier L; Störk S; Kherad B; Laufs U
    Clin Res Cardiol; 2018 Jan; 107(1):1-19. PubMed ID: 29018938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HFA-PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation.
    Seoudy H; von Eberstein M; Frank J; Thomann M; Puehler T; Lutter G; Lutz M; Bramlage P; Frey N; Saad M; Frank D
    ESC Heart Fail; 2022 Apr; 9(2):1071-1079. PubMed ID: 35092186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.